A Study of Donanemab (LY3002813) in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2023-04-20
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the
blood stream and how long it takes the body to remove it when administered as single dose in
healthy participants. The study will also evaluate the safety and tolerability of donanemab.
The study will last up to approximately 22 weeks.